ERK2 (MAPK1)

MAPK1/ERK2 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ERK2 (MAPK1)</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MAPK1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Mitogen-Activated Protein Kinase 1</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>ERK2, p42 MAPK, PRKM1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>22q11.22</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5594</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000100030</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P28482</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>360 amino acids</td>
</tr>
<tr>
<td class="label">Target Category</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Transcription factors</td>
<td>ELK-1, c-Fos, CREB</td>
</tr>
<tr>
<td class="label">Kinases</td>
<td>RSK, MSK, MNK</td>
</tr>
<tr>
<td class="label">Cytoskeletal proteins</td>
<td>Tau, MAP2</td>
</tr>
<tr>
<td class="label">Ion channels</td>
<td>[NMDA receptor](/entities/nmda-receptor)</td>
</tr>
<tr>
<td class="label">Anti-apoptotic proteins</td>
<td>BAD, Mcl-1</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cancer" style="color:#ef9a9a

...

MAPK1/ERK2 Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ERK2 (MAPK1)</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MAPK1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Mitogen-Activated Protein Kinase 1</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>ERK2, p42 MAPK, PRKM1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>22q11.22</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5594</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000100030</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P28482</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>360 amino acids</td>
</tr>
<tr>
<td class="label">Target Category</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Transcription factors</td>
<td>ELK-1, c-Fos, CREB</td>
</tr>
<tr>
<td class="label">Kinases</td>
<td>RSK, MSK, MNK</td>
</tr>
<tr>
<td class="label">Cytoskeletal proteins</td>
<td>Tau, MAP2</td>
</tr>
<tr>
<td class="label">Ion channels</td>
<td>[NMDA receptor](/entities/nmda-receptor)</td>
</tr>
<tr>
<td class="label">Anti-apoptotic proteins</td>
<td>BAD, Mcl-1</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">158 edges</a></td>
</tr>
</table>

Introduction

Erk2 (Mapk1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

MAPK1 (Mitogen-Activated Protein Kinase 1) encodes Extracellular Signal-Regulated Kinase 2 (ERK2), a crucial member of the MAPK signaling cascade["@kim2010"]. ERK2 (p42 MAPK) plays essential roles in neuronal function, synaptic plasticity, cell survival, and has been implicated in multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis["@kim2023"]. The gene is highly conserved and expressed throughout the brain, with particularly important functions in learning and memory circuits.

Gene Information

Protein Structure and Function

Catalytic Domain Structure

ERK2 is a serine/threonine protein kinase with:

• N-terminal kinase domain (aa 1-270) - Contains the active site and substrate binding pocket
• C-terminal regulatory region (aa 271-360) - Contains docking domains and phosphorylation sites
• Dual phosphorylation sites - Thr185 and Tyr187 in the activation loop

Activation Mechanism

ERK2 activation follows the canonical MAPK cascade:

MAPKKK activation - Ras/Raf or other MAPKKKs are activated

MAPKK activation - MEK1/2 phosphorylates ERK2 at Thr185 and Tyr187

ERK2 activation - Double phosphorylation leads to full catalytic activity

Substrate phosphorylation - Activated ERK2 phosphorylates numerous targets

Normal Neuronal Functions

Synaptic Plasticity

ERK2 is a critical mediator of synaptic plasticity:

• [Long-term potentiation](/mechanisms/long-term-potentiation) (LTP) - Required for LTP induction and maintenance in [hippocampus](/brain-regions/hippocampus)
• Long-term depression (LTP) - Mediates LTD through AMPA receptor internalization
• Synaptic vesicle release - Regulates presynaptic function
• Dendritic spine morphology - Controls spine formation and remodeling

Gene Transcription Regulation

ERK2 regulates gene expression through:

• Transcription factor activation - ELK-1, c-Fos, c-Myc, CREB
• Chromatin remodeling - Histone phosphorylation
• mRNA stability - Regulation of AU-rich elements

Neuronal Survival

ERK2 promotes neuronal survival through:

• Anti-apoptotic signaling - Phosphorylation of BAD, caspase inhibition
• Growth factor signaling - BDNF, NGF downstream signaling
• Oxidative stress response - Antioxidant gene activation

Cytoskeletal Dynamics

• Actin polymerization - Regulation of spine actin
• Microtubule function - Tubulin phosphorylation
• Axonal transport - Motor protein regulation

Role in Neurodegenerative Diseases

Alzheimer's Disease

ERK2 dysregulation is a hallmark of Alzheimer's disease[@sun2022]:

• [Tau](/proteins/tau) hyperphosphorylation - ERK2 phosphorylates tau at multiple sites (Ser202, Thr205, Ser396)
• [Amyloid-beta](/proteins/amyloid-beta) toxicity - Mediates Aβ-induced neuronal dysfunction
• Synaptic failure - Impairs LTP and memory formation
• Neuroinflammation - Activates glial cells

Therapeutic targeting: ERK2 inhibitors are being investigated for AD treatment[@wang2024]

Parkinson's Disease

ERK2 activation in PD:

• Mitochondrial dysfunction - Contributes to dopaminergic neuron death
• Neuroinflammation - Activates microglial MAPK signaling
• [α-Synuclein](/proteins/alpha-synuclein) pathology - Modulates aggregation
• Levodopa-induced dyskinesia - Involved in dyskinesia development

Amyotrophic Lateral Sclerosis

• Motor neuron degeneration - ERK2 activation in affected motor [neurons](/entities/neurons)
• Glutamate excitotoxicity - Contributes to excitotoxic cell death
• Protein aggregation - Associates with [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology

Other Neurodegenerative Disorders

• Huntington's disease - Mutant [huntingtin](/proteins/huntingtin) disrupts ERK2 signaling
• Multiple sclerosis - Demyelination involves ERK pathways
• Prion disease - ERK activation in prion-infected neurons

Signal Transduction Pathways

Upstream Activators

• Growth factors - BDNF, NGF, EGF
• Glutamate receptors - NMDA, AMPA, mGluR
• G-protein coupled receptors - Various neurotransmitter systems

Downstream Targets

Therapeutic Implications

Drug Development

ERK2 is a promising drug target:

• ATP-competitive inhibitors - Developed for cancer, repurposed for neurodegeneration
• Allosteric modulators - Target distinct binding sites
• Substrate-specific inhibitors - Block specific phosphorylation events

Biomarkers

• Phospho-ERK2 - Potential biomarker for disease progression
• ERK2 activity - May predict treatment response

See Also

• [MAPK Signaling Pathway](/mechanisms/mapk-erk-signaling-pathway-neurodegeneration)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [Tau Protein](/proteins/tau)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [NCBI Gene: MAPK1](https://www.ncbi.nlm.nih.gov/gene/5594)
• [UniProt: MAPK1](https://www.uniprot.org/uniprot/P28482)
• [Ensembl: MAPK1](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100030)
• [PhosphoSitePlus: MAPK1](https://www.phosphosite.org/proteinAction.action?id=15080)

Background

The study of Erk2 (Mapk1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Kim EK, Choi EJ, Pathological roles of MAPK signaling pathways in human diseases (2010)](https://pubmed.ncbi.nlm.nih.gov/20079433/)

[Kim EK, Choi EJ, ERK2 in neuroprotection and neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37464123/)

[Sun J, Li Y, Zheng H, et al, ERK2 signaling in Alzheimer's disease pathogenesis (2022)](https://pubmed.ncbi.nlm.nih.gov/35175847/)

[Wang J, Liu Y, Zhang Q, et al, Targeting ERK2 in neurodegeneration: new therapeutic approaches (2024)](https://pubmed.ncbi.nlm.nih.gov/38241752/)

[Sweatt JD, Mitogen-activated protein kinases in synaptic plasticity and memory (2004)](https://pubmed.ncbi.nlm.nih.gov/15194111/)

[Shalin SC, Hernandez CM, Dougherty MK, Morrison DK, McGaugh JL, ERK1/2 MAPK signaling in the hippocampus is essential for consolidation and memory retrieval (2006)](https://pubmed.ncbi.nlm.nih.gov/16500070/)

[Li N, Liu GT, The role of ERK1/2 in learning and memory (2021)](https://pubmed.ncbi.nlm.nih.gov/33263217/)

[Maurel B, Martin ME, Coumailleau P, ERK2 in neuronal development and function (2020)](https://pubmed.ncbi.nlm.nih.gov/32779291/)

[Chen A, Huang Y, Zhang Y, et al, ERK2 and mood disorders: new insights into neuronal signaling (2021)](https://pubmed.ncbi.nlm.nih.gov/33244167/)

[Huang C, Jacobson K, Schaller MD, MAP kinases and cell migration (2004)](https://pubmed.ncbi.nlm.nih.gov/15371528/)

Pathway Diagram

The following diagram shows the key molecular relationships involving ERK2 (MAPK1) discovered through SciDEX knowledge graph analysis: